Emergent BioSolutions reported GAAP net income of $74.3 million for the six months ended December 31, 2021, down 7.4% from $80.2 million in the prior year. Revenue increased 26.1% to $740.5 million from $587.2 million a year earlier.
Emergent BioSolutions reported GAAP net income of $74.3 million for the six months ended December 31, 2021, down 7.4% from $80.2 million in the prior year. Revenue increased 26.1% to $740.5 million from $587.2 million a year earlier. 
investors.emergentbiosolutions.com
English (US) 